1. Scrip
  2. >>Business
  3. >>Strategy

Equillium Will Study In-Licensed Itolizumab In Three Indications In 2019

 
• By Mandy Jackson

Emerging Company Profile: Equillium in-licensed the CD6 inhibitor EQ001 – Biocon's Alzumab (itolizumab), approved in India for psoriasis – and will begin clinical trials for three autoimmune disease indications this year; a Phase Ib/II aGvHD study is under way.

Emerging Company Profile Regular column feature image Version 2

Equillium Inc. came together around EQ001 (itolizumab), a CD6 inhibitor for autoimmune and inflammatory diseases, when the company's founders were looking to transition into a new venture. Now, with an initial public offering completed last year, San Diego-based Equillium is moving into multiple proof-of-concept studies to see if its monoclonal antibody previously nestled away in an Indian biosimilar specialist's portfolio really was a hidden gem.

Chairman and CEO Daniel Bradbury wasn't looking to jump right into another C-suite role back in 2012 after his prior company – the diabetes drug maker Amylin Pharmaceuticals Inc., where he was the president and CEO – was sold to Bristol-Myers Squibb Co. for $7bn. (Also see " Amylin gets full value from $7bn BMS/AZ acquisition " - Scrip, 2 July, 2012

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.